TQB3912
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for TQB3912, covering 2025-08-11 to 2025-12-12. Get the full timeline:
Most recent: Clinical Trial Update: Clinical Trial of Evaluating TQB3912 Tablets Combined With Fulvestrant Injection±TQB3616 Capsules for Locally Advanced or Metastatic Hormone Receptor(HR)-Positive and Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer [Phase 1, Phase 2]